<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04380467</url>
  </required_header>
  <id_info>
    <org_study_id>15.0236</org_study_id>
    <nct_id>NCT04380467</nct_id>
  </id_info>
  <brief_title>Vitamin D Supplementation in CKD - Vascular Function, Structure and Immune Regulation</brief_title>
  <official_title>Impact of Vitamin D Supplementation on Vascular Function, Vascular Structure and Immune Regulation in Patients With Chronic Kidney Disease and Low Vitamin D Levels - A Pilot Randomised Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St George's, University of London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St George's, University of London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A pilot study to assess feasibility of methods of an observer-blinded randomised controlled
      trial of the effect of vitamin D supplementation in Chronic Kidney Disease and low vitamin D
      levels on markers of vascular function (Flow Mediated Dilatation of Brachial Artery),
      vascular structure (Carotid Intima Media Thickness) and Immune Regulation (frequencies of
      CD4+CD28null T lymphocytes ad Regulatory T lymphocytes).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a single (observer) blinded feasibility pilot randomised study. Study subjects
      will be recruited from clinics run by St George's Hospital Renal Department and randomised to
      treatment arm or no treatment arm.

      In treatment arm, six doses of vitamin D tablets (cholecalciferol 100,000 IU, five capsules
      total) will be administered on weeks 0, 4, 8, 12, 16 and 20. In the no-treatment arm the
      participants receive no cholecalciferol. Participants will have serum calcium levels measured
      at week 12.

      All participants will undergo estimation of endothelial function, carotid intima-media
      thickness, CD4+CD28null and regulatory T cell frequency in week 0 and week 26. The observer
      will be blinded to whether the patient is in the treatment or no-treatment arm whilst the
      following tests are performed:

        1. Measurement of Brachial Artery Flow Mediated Dilatation

        2. Measurement of Carotid Intima Media Thickness

        3. Quantification of CD4+CD28null and regulatory T cell frequency

      The pilot study will assess feasibility of the study methods.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recruitment rate</measure>
    <time_frame>3 months</time_frame>
    <description>Percentage of patients recruited from those eligible for the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Retention rate</measure>
    <time_frame>6 months</time_frame>
    <description>Percentage of patients recruited who completed the follow up investigations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acceptability to patients of randomisation procedures</measure>
    <time_frame>6 months</time_frame>
    <description>Acceptability as assessed by quantitative and qualitative analysis of Participant Experience Survey</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Randomisation procedure</measure>
    <time_frame>6 months</time_frame>
    <description>Comparison of baseline indices of two patient groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maintenance of single (observer) blinding</measure>
    <time_frame>6 months</time_frame>
    <description>Incidences of unblinding of study investigator</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adherence to vitamin D supplementation</measure>
    <time_frame>6 months</time_frame>
    <description>Subjective adherence as assessed by Participant Experience Survey and biochemical correlation by comparison of follow up vitamin D levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Witnessed change in FMD between treated and untreated subjects</measure>
    <time_frame>6 months</time_frame>
    <description>Flow Mediated Dilatation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Witnessed change in CIMT between treated and untreated subjects</measure>
    <time_frame>6 months</time_frame>
    <description>Carotid Intima Media Thickness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Witnessed change in T lymphocyte subset frequency between treated and untreated subjects</measure>
    <time_frame>6 months</time_frame>
    <description>CD4+CD28null T lymphocytes and Regulatory T cells as determined by flow cytometry of whole blood</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Atherosclerosis</condition>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Vitamin D Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Six doses of cholecalciferol 100,000units (5x aviticol 20,000units capsules) administered monthly over 20 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No vitamin D given</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D (cholecalciferol)</intervention_name>
    <description>(aviticol) 5x 20,000unit capsules administered monthly over 20 weeks</description>
    <arm_group_label>Vitamin D Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-80 years

          2. Calcium &lt; 2.58mmol/l

          3. On an ACE inhibitor/ARB

          4. Vitamin D &lt;75nmol/l

          5. eGFR 15- 60ml/min/1.73m2 and stable

          6. Informed consent to participate

        Exclusion Criteria:

          1. Patients already on Vitamin D or calcium supplementation

          2. Patients with known malignancies

          3. Patients with autoimmune conditions

          4. Patients with heart failure (ejection fraction &lt;40%, Plasma NT pro-BNP&gt;500pg/ml)

          5. Patients with active infection

          6. Rapidly deteriorating renal function

          7. Recent Acute coronary syndrome or cerebro-vascular event (within the last 6 months)

          8. Uncontrolled hypertension (BP&gt;160 systolic)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Debasish Banarjee</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Georges University NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Debasish Banerjee</name>
      <address>
        <city>London</city>
        <state>Tooting</state>
        <zip>sw17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>July 19, 2016</study_first_submitted>
  <study_first_submitted_qc>May 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2020</study_first_posted>
  <last_update_submitted>May 7, 2020</last_update_submitted>
  <last_update_submitted_qc>May 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vitamin D</keyword>
  <keyword>Cholecalciferol</keyword>
  <keyword>Chronic Kidney Disease</keyword>
  <keyword>Cardiovascular Disease</keyword>
  <keyword>Atherosclerosis</keyword>
  <keyword>Flow Mediated Dilatation</keyword>
  <keyword>Carotid Intima Media Thickness</keyword>
  <keyword>CD4+CD28null T lymphocyte</keyword>
  <keyword>Regulatory T lymphocyte</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

